Diabetes patients who add dipeptidyl peptidase-4 (DPP-4) inhibitors to their metformin therapy have a lower risk of stroke and hypoglycemia than patients who take add-on sulfonylureas, according to a study. The research shows that, compared with add-on sulfonylureas, DPP-4 inhibitors also confer lower risks for all-cause death and major adverse cardiovascular adverse events (MACE) when used with metformin therapy in patients with type 2 diabetes.  DPP-4 inhibitors were associated with lower risks for all-cause death, stroke and hypoglycemia compared with sulfonylureas, but had no effect on heart attack risk and hospitalization for heart failure. Ou S-M, Shih C-J, Chao P-W et al., Annals of Internal Medicine Oct. 13, 2015. doi:10.7326/M15-0308